Tuberculosis (Pulmonary) - Causes, Treatment & When to See a Doctor

```html

What is Tuberculosis (Pulmonary)?

Pulmonary tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis that primarily affects the lungs. When inhaled, the bacteria settle in the air‑spaces and alveoli, where they can multiply and trigger an immune response. Most people who become infected never develop active disease; instead, the bacteria remain dormant in a state called latent TB infection (LTBI). When the immune system is weakened—or in a small percentage of people—those dormant organisms reactivate, leading to symptomatic, contagious pulmonary TB.

According to the World Health Organization (WHO), TB remains one of the top ten causes of death worldwide, with an estimated 10 million new cases each year and over 1.5 million deaths in 2022. While TB can affect any organ, the lungs are the most common site, accounting for about 85 % of all cases.

Common Causes

Unlike many non‑communicable illnesses, pulmonary TB is not caused by lifestyle factors alone; it results from exposure to the bacteria plus conditions that impair the body’s ability to contain it. The following factors increase the risk of developing active pulmonary TB:

• Close, prolonged exposure to an infected person – especially in crowded or poorly ventilated settings.
• HIV infection – weakens cellular immunity, making reactivation of latent TB far more likely.
• Diabetes mellitus – high blood glucose impairs immune function.
• Immunosuppressive therapy – including corticosteroids, TNF‑α inhibitors, and chemotherapy.
• Malnutrition or severe weight loss – reduces the body's ability to mount an effective immune response.
• Silicosis or other occupational lung diseases – silica dust damages macrophages that normally destroy TB bacteria.
• Substance abuse – especially alcohol dependence and injectable drug use.
• Renal failure or dialysis – associated immunologic alterations.
• Young age (especially children under 5) – immature immune systems increase susceptibility.
• Recent travel or immigration from high‑burden countries – higher likelihood of exposure.

Associated Symptoms

Symptoms of active pulmonary TB typically develop gradually over weeks to months. The classic triad includes a persistent cough, fever, and night sweats, but many additional features may appear.

• Chronic cough lasting >2 weeks, often with sputum production; may be bloody (hemoptysis).
• Low‑grade fever that may rise in the evenings.
• Night sweats that soak clothing and bedding.
• Unexplained weight loss (often 5–10 % of body weight).
• Fatigue and weakness that interfere with daily activities.
• Chest pain – usually pleuritic (sharp pain that worsens with deep breathing).
• Loss of appetite and general malaise.
• Shortness of breath in advanced disease or when extensive lung tissue is involved.

Because the symptoms are nonspecific, TB can be mistaken for other respiratory illnesses such as pneumonia, chronic bronchitis, or lung cancer. That’s why a thorough diagnostic work‑up is essential.

When to See a Doctor

Prompt medical evaluation is crucial whenever you notice any of the following:

• A cough that persists for more than two weeks, especially if you produce sputum or notice blood.
• Unexplained fever, night sweats, or weight loss.
• Recent exposure to someone diagnosed with active TB.
• Underlying conditions that weaken immunity (e.g., HIV, diabetes, use of immunosuppressants).
• Chest pain or difficulty breathing that worsens over time.

Early detection shortens the infectious period, improves treatment outcomes, and reduces the chance of complications such as lung cavitation or spread to other organs.

Diagnosis

Diagnosing pulmonary TB combines clinical assessment with laboratory and radiologic testing.

1. Medical History and Physical Exam

• Assess symptom duration, risk factors, and exposure history.
• Listen for abnormal breath sounds (e.g., crackles, diminished vesicular sounds) that suggest lung involvement.

2. Microbiologic Tests

• Sputum smear microscopy – Ziehl‑Neelsen or fluorescent staining to detect acid‑fast bacilli; provides rapid, though less sensitive, results.
• Sputum culture – Gold standard; grows M. tuberculosis on solid (Lowenstein‑Jensen) or liquid media. Takes 2–8 weeks but confirms species and drug susceptibility.
• Rapid molecular assays (e.g., GeneXpert MTB/RIF) – Detect bacterial DNA and resistance to rifampin within 2 hours; now recommended as the initial test by WHO and CDC.
• Interferon‑γ release assays (IGRAs) or tuberculin skin test (TST) – Identify latent infection but do not differentiate active disease.

3. Radiologic Evaluation

• Chest X‑ray – Often shows infiltrates, cavitary lesions, or hilar lymphadenopathy; patterns differ by disease stage.
• Chest CT scan – Provides detailed view of cavitations, nodules, or pleural effusions, useful for atypical presentations.

4. Additional Tests (when indicated)

• Bronchoscopy with bronchoalveolar lavage if sputum is negative but suspicion remains high.
• HIV testing – recommended for all patients with TB because co‑infection changes management.
• Baseline liver function tests and renal panels before starting therapy.

Treatment Options

Tuberculosis is a curable disease, but successful therapy depends on taking medications exactly as prescribed for the full course.

1. First‑Line Anti‑TB Drug Regimen

The standard 6‑month regimen (often abbreviated “RIPE”) includes:

• Rifampin (R) – Bactericidal, kills actively replicating bacteria.
• Isoniazid (I) – Highly effective against latent and active organisms.
• Pyrazinamide (P) – Works best in acidic environments; short‑course (first 2 months).
• Ethambutol (E) – Prevents emergence of resistance while susceptibility is pending.

Typical schedule:

• Intensive phase: 2 months of RIPE daily (or 3‑month thrice‑weekly in some programs).
• Continuation phase: 4 months of rifampin + isoniazid (daily or thrice‑weekly).

2. Management of Drug‑Resistant TB

• Multidrug‑resistant TB (MDR‑TB) – Resistant to at least rifampin and isoniazid; requires second‑line agents (e.g., fluoroquinolones, injectable aminoglycosides) for 18‑24 months.
• Extensively drug‑resistant TB (XDR‑TB) – Resistant to fluoroquinolones and at least one injectable; treated with newer drugs such as bedaquiline, delamanid, and linezolid under specialist supervision.

3. Adjunctive Therapies

• Vitamin B6 (pyridoxine) – Given with isoniazid to prevent peripheral neuropathy.
• Corticosteroids – Indicated in TB meningitis, pericarditis, or severe airway obstruction, but not routine for uncomplicated pulmonary TB.
• Nutrition support – High‑calorie diet and protein supplementation improve recovery.

4. Home Care and Lifestyle Measures

• Complete the full medication course; never stop early even if feeling better.
• Take drugs on an empty stomach (most are absorbed better with food, but rifampin may cause nausea if taken with a full meal).
• Attend all scheduled follow‑up appointments for sputum monitoring and liver function checks.
• Avoid alcohol while on therapy, especially with isoniazid and pyrazinamide, to reduce liver toxicity.
• Maintain adequate hydration and rest.

Prevention Tips

Because TB is airborne, public‑health measures focus on reducing exposure and preventing progression from latent infection to active disease.

• Vaccination – Bacille Calmette‑Guérin (BCG) vaccine offers modest protection against severe forms of TB in children; its efficacy against pulmonary disease in adults varies.
• Identify and treat latent TB infection (LTBI) in high‑risk groups (e.g., recent contacts, HIV‑positive individuals) using isoniazid for 6–9 months or rifampin for 4 months.
• Infection control in healthcare settings – Use N95 respirators, negative‑pressure rooms, and UV germicidal lamps for patients with suspected/confirmed TB.
• Improve ventilation – Open windows, use fans, or install mechanical ventilation in crowded homes, shelters, prisons, and workplaces.
• Prompt diagnosis and treatment – Reduces the period of contagiousness; patients are usually non‑infectious after 2 weeks of effective therapy.
• Healthy lifestyle – Adequate nutrition, regular exercise, smoking cessation, and control of diabetes lower susceptibility.
• Travel precautions – For travelers to high‑burden regions, avoid prolonged exposure to crowds, wear masks when appropriate, and seek evaluation if cough develops within 3 months of return.

Emergency Warning Signs

Key Take‑aways

Pulmonary tuberculosis remains a major global health threat, but it is both preventable and curable. Understanding the risk factors, recognizing the gradual yet persistent symptoms, and seeking timely medical evaluation are essential steps toward recovery and protecting others.

For more detailed guidance, consult reputable sources such as the CDC TB page, the WHO Global Tuberculosis Programme, and the Mayo Clinic. If you suspect TB or have been exposed, contact a healthcare provider without delay.

```